癌症治疗中的一次面部智能肌肉活动电位测量
A SMAP in the face for cancer.
作者信息
Shenolikar Shirish
出版信息
J Clin Invest. 2017 Jun 1;127(6):2048-2050. doi: 10.1172/JCI94763. Epub 2017 May 15.
Abstract
Observed deficits in protein phosphatase 2A (PP2A) function in a variety of human cancers have stimulated drug discovery efforts aimed at restoring PP2A function to inhibit tumor growth. Work published by Sangodkar et al. in this issue of the JCI describes the characterization of orally available small molecule activators of PP2A (SMAPs). These SMAPs attenuated mitogenic signaling and triggered apoptosis in KRAS-mutant lung cancer cells and inhibited tumor growth in murine models. Tumors with mutations in the SMAP-binding site of the PP2A A subunit displayed resistance to SMAPs. Future studies that identify the PP2A-regulated events targeted by SMAPs should guide critical decisions about which cancers might be best treated with these molecules. This study provides encouraging evidence in favor of SMAPs as potential anticancer drugs.
摘要
在多种人类癌症中观察到的蛋白磷酸酶2A（PP2A）功能缺陷，激发了旨在恢复PP2A功能以抑制肿瘤生长的药物研发工作。桑戈德卡尔等人在本期《临床研究杂志》上发表的研究描述了PP2A口服小分子激活剂（SMAPs）的特性。这些SMAPs减弱了促有丝分裂信号传导，触发了KRAS突变肺癌细胞的凋亡，并在小鼠模型中抑制了肿瘤生长。PP2A A亚基的SMAP结合位点发生突变的肿瘤对SMAPs具有抗性。确定SMAPs靶向的PP2A调节事件的未来研究，应指导关于哪些癌症可能最适合用这些分子治疗的关键决策。这项研究为支持SMAPs作为潜在抗癌药物提供了令人鼓舞的证据。
相似文献
1
A SMAP in the face for cancer.癌症治疗中的一次面部智能肌肉活动电位测量
J Clin Invest. 2017 Jun 1;127(6):2048-2050. doi: 10.1172/JCI94763. Epub 2017 May 15.
2
Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.肿瘤抑制蛋白PP2A的激活可抑制KRAS驱动的肿瘤生长。
J Clin Invest. 2017 Jun 1;127(6):2081-2090. doi: 10.1172/JCI89548. Epub 2017 May 15.
3
Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers.蛋白磷酸酶 2A 激活作为治疗 MYC 驱动型癌症的策略。
J Biol Chem. 2020 Jan 17;295(3):757-770. doi: 10.1074/jbc.RA119.011443. Epub 2019 Dec 10.
4
Select Stabilization of a Tumor-Suppressive PP2A Heterotrimer.选择肿瘤抑制性 PP2A 异三聚体的稳定化。
Trends Pharmacol Sci. 2020 Sep;41(9):595-597. doi: 10.1016/j.tips.2020.06.008. Epub 2020 Jul 2.
5
Arsenic trioxide inhibits CXCR4-mediated metastasis by interfering miR-520h/PP2A/NF-κB signaling in cervical cancer.三氧化二砷通过干扰宫颈癌中miR-520h/PP2A/NF-κB信号通路抑制CXCR4介导的转移。
Ann Surg Oncol. 2014 Dec;21 Suppl 4:S687-95. doi: 10.1245/s10434-014-3812-5. Epub 2014 Jul 22.
6
PP2A inhibitors induce apoptosis in pancreatic cancer cell line PANC-1 through persistent phosphorylation of IKKα and sustained activation of the NF-κB pathway.PP2A 抑制剂通过持续磷酸化 IKKα 和持续激活 NF-κB 通路诱导胰腺癌细胞系 PANC-1 凋亡。
Cancer Lett. 2011 May 28;304(2):117-27. doi: 10.1016/j.canlet.2011.02.009. Epub 2011 Mar 3.
7
Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells.拉帕替尼抑制CIP2A/PP2A/p-Akt信号传导并诱导三阴性乳腺癌细胞凋亡。
Oncotarget. 2016 Feb 23;7(8):9135-49. doi: 10.18632/oncotarget.7035.
8
PP2A: unveiling a reluctant tumor suppressor.蛋白磷酸酶2A：揭示一种“不情愿”的肿瘤抑制因子
Cell. 2007 Jul 13;130(1):21-4. doi: 10.1016/j.cell.2007.06.034.
9
Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.唑来膦酸联合丝氨酸/苏氨酸磷酸酶抑制剂通过降低 PP1 和 PP2A 的活性，增强激素难治性前列腺癌细胞系的细胞毒性和凋亡。
BJU Int. 2012 Dec;110(11 Pt C):E1147-54. doi: 10.1111/j.1464-410X.2012.11392.x. Epub 2012 Aug 9.
10
Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.索拉非尼和硼替佐米在肝癌中的协同作用涉及 PP2A 依赖性 Akt 失活。
J Hepatol. 2010 Jan;52(1):88-95. doi: 10.1016/j.jhep.2009.10.011. Epub 2009 Oct 23.
引用本文的文献
1
Defining the Protein Phosphatase 2A (PP2A) Subcomplexes That Regulate FoxO Transcription Factor Localization.定义调节FoxO转录因子定位的蛋白磷酸酶2A（PP2A）亚复合物
Cells. 2025 Feb 27;14(5):342. doi: 10.3390/cells14050342.
2
Integrated stress response plasticity governs normal cell adaptation to chronic stress via the PP2A-TFE3-ATF4 pathway.整合应激反应可塑性通过PP2A-TFE3-ATF4途径调控正常细胞对慢性应激的适应。
Cell Death Differ. 2024 Dec;31(12):1761-1775. doi: 10.1038/s41418-024-01378-3. Epub 2024 Sep 30.
3
SRC inhibition enables formation of a growth suppressive MAGI1-PP2A complex in isocitrate dehydrogenase-mutant cholangiocarcinoma.SRC 抑制可使异柠檬酸脱氢酶突变胆管癌中生长抑制性 MAGI1-PP2A 复合物形成。
Sci Transl Med. 2024 May 15;16(747):eadj7685. doi: 10.1126/scitranslmed.adj7685.
4
Integrated stress response plasticity governs normal cell adaptation to chronic stress via the PP2A-TFE3-ATF4 pathway.整合应激反应可塑性通过PP2A-TFE3-ATF4途径调控正常细胞对慢性应激的适应性。
Res Sq. 2024 Mar 28:rs.3.rs-4013396. doi: 10.21203/rs.3.rs-4013396/v1.
5
Small-Molecule-Mediated Stabilization of PP2A Modulates the Homologous Recombination Pathway and Potentiates DNA Damage-Induced Cell Death.小分子介导的 PP2A 稳定调控同源重组途径并增强 DNA 损伤诱导的细胞死亡。
Mol Cancer Ther. 2023 May 4;22(5):599-615. doi: 10.1158/1535-7163.MCT-21-0880.
6
Pleiotropy of PP2A Phosphatases in Cancer with a Focus on Glioblastoma Wildtype.PP2A磷酸酶在癌症中的多效性，重点关注胶质母细胞瘤野生型。
Cancers (Basel). 2022 Oct 25;14(21):5227. doi: 10.3390/cancers14215227.
7
Biased holoenzyme assembly of protein phosphatase 2A (PP2A): From cancer to small molecules.蛋白磷酸酶 2A（PP2A）的偏倚全酶组装：从癌症到小分子。
J Biol Chem. 2022 Dec;298(12):102656. doi: 10.1016/j.jbc.2022.102656. Epub 2022 Nov 1.
8
RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth.RABL6A 通过抑制抑瘤性的 PP2A/AKT 信号通路促进胰腺神经内分泌肿瘤的生长。
J Clin Invest. 2019 Mar 4;129(4):1641-1653. doi: 10.1172/JCI123049.
9
miR-19b enhances proliferation and apoptosis resistance via the EGFR signaling pathway by targeting PP2A and BIM in non-small cell lung cancer.miR-19b 通过靶向非小细胞肺癌中的 PP2A 和 BIM 增强 EGFR 信号通路促进增殖和抗凋亡。
Mol Cancer. 2018 Feb 19;17(1):44. doi: 10.1186/s12943-018-0781-5.
本文引用的文献
1
Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.肿瘤抑制蛋白PP2A的激活可抑制KRAS驱动的肿瘤生长。
J Clin Invest. 2017 Jun 1;127(6):2081-2090. doi: 10.1172/JCI89548. Epub 2017 May 15.
2
PP2A Inhibitor PME-1 Drives Kinase Inhibitor Resistance in Glioma Cells.PP2A 抑制剂 PME-1 驱动神经胶质瘤细胞对激酶抑制剂的耐药性。
Cancer Res. 2016 Dec 1;76(23):7001-7011. doi: 10.1158/0008-5472.CAN-16-1134. Epub 2016 Sep 26.
3
The broken "Off" switch in cancer signaling: PP2A as a regulator of tumorigenesis, drug resistance, and immune surveillance.癌症信号通路中失灵的“关闭”开关：蛋白磷酸酶2A作为肿瘤发生、耐药性和免疫监视的调节因子
BBA Clin. 2016 Aug 3;6:87-99. doi: 10.1016/j.bbacli.2016.08.002. eCollection 2016 Dec.
4
All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase.条条大路通PP2A：挖掘这种磷酸酶的治疗潜力。
FEBS J. 2016 Mar;283(6):1004-24. doi: 10.1111/febs.13573. Epub 2015 Nov 14.
5
Targeting cancer with kinase inhibitors.用激酶抑制剂靶向治疗癌症。
J Clin Invest. 2015 May;125(5):1780-9. doi: 10.1172/JCI76094. Epub 2015 May 1.
6
Restricted protein phosphatase 2A targeting by Merkel cell polyomavirus small T antigen.默克尔细胞多瘤病毒小T抗原对蛋白磷酸酶2A的靶向作用受限。
J Virol. 2015 Apr;89(8):4191-200. doi: 10.1128/JVI.00157-15. Epub 2015 Jan 28.
7
Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia.吩噻嗪类药物诱导 T 细胞急性淋巴细胞白血病中 PP2A 介导的细胞凋亡。
J Clin Invest. 2014 Feb;124(2):644-55. doi: 10.1172/JCI65093. Epub 2014 Jan 9.
8
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.PP2A 激活剂药物选择性根除 TKI 耐药性慢性髓性白血病干细胞。
J Clin Invest. 2013 Oct;123(10):4144-57. doi: 10.1172/JCI68951. Epub 2013 Sep 3.
9
SV40 small T antigen and PP2A phosphatase in cell transformation.细胞转化中的SV40小T抗原与PP2A磷酸酶
Cancer Metastasis Rev. 2008 Jun;27(2):137-46. doi: 10.1007/s10555-008-9116-0.
10
The tumor suppressor PP2A Abeta regulates the RalA GTPase.肿瘤抑制因子PP2A Abeta调节RalA GTP酶。
Cell. 2007 Jun 1;129(5):969-82. doi: 10.1016/j.cell.2007.03.047.
Zotero 插件